Vasopressin
Also known as: Arginine vasopressin · AVP · antidiuretic hormone · ADH
The endogenous nonapeptide antidiuretic hormone with distinctive central memory-modulation effects — the parent compound of the classical vasopressin-family cognitive research programme and the direct hormone from which DDAVP and DGAVP were engineered.
Vasopressin is the endogenous nonapeptide antidiuretic hormone with distinctive central memory-modulation effects; parent compound of DDAVP and DGAVP, licensed for antidiuretic clinical use.
Evidence tier: A — ≥1 RCT + meta-analysis or approved clinical use
- Category
- Cognitive Enhancement
- Half-life
- Very short plasma half-life (approximately 10-20 minutes)
Section 1
Overview
Vasopressin is the endogenous nonapeptide antidiuretic hormone produced by hypothalamic paraventricular and supraoptic neurons and released peripherally to regulate water balance via V2 receptor-mediated water reabsorption in the renal collecting ducts, and centrally where it modulates memory, social behaviour, and stress response through V1a and V1b receptor engagement. It is a licensed pharmaceutical for diabetes insipidus and other hyponatraemia-associated clinical indications.
The compound's cognitive-relevance emerges from the classical De Wied laboratory work in the 1960s-90s that established peptides as memory-modulating research tools. Vasopressin's central memory effects are mediated by V1a receptor engagement on hippocampal and amygdalar neuronal populations, providing the mechanism-of-action framework that motivated the development of the derivative analogues DDAVP (V2-selective for antidiuretic clinical use) and DGAVP (V1a/V1b-preferring for central-effect research).
Direct current cognitive-research use of parent vasopressin is limited by the compound's peripheral pressor and antidiuretic effects that complicate research-context administration. The derivative analogues have largely replaced parent vasopressin for cognitive-endpoint research applications, but the parent compound retains historical and mechanistic reference significance in the vasopressin-family cognitive research programme.
Section 2
Discovery & History
- Isolated and structurally characterised in the 1950s by Vincent du Vigneaud, who received the 1955 Nobel Prize in Chemistry for the work — the first peptide hormone to be synthesised chemically (alongside oxytocin).
- Licensed for clinical use as vasopressin injection for diabetes insipidus and other hyponatraemia-associated indications.
- Extensively characterised across the 1960s-90s De Wied laboratory research programme establishing the vasopressin-family cognitive-effect research framework.
- Directly informed the development of the derivative analogues DDAVP (V2-selective) and DGAVP (V1a/V1b-preferring).
- Retains licensed clinical use in the antidiuretic indications; cognitive-research use is largely displaced by the derivative analogues.
Section 3
Mechanism of Action
- 1V2 receptor agonism on renal collecting-duct cells — the antidiuretic mechanism that drives the licensed clinical indications via aquaporin-2 upregulation and water reabsorption.
- 2V1a receptor agonism on vascular smooth muscle — the peripheral pressor effect that limits parent vasopressin research use relative to the V2-selective DDAVP.
- 3Central V1a receptor engagement in the hippocampus and amygdala — the memory-modulation mechanism-of-action that motivated the classical De Wied laboratory research and provides the cognitive-relevance framework.
- 4Central V1b receptor engagement in the pituitary — modulation of ACTH release and downstream HPA-axis effects that contribute to the observed neuroendocrine effects.
- 5Modulation of monoamine systems in preclinical models, providing additional angles for the cognitive and mood effects observed in the vasopressin-family research literature.
- 6Effects on cerebral blood flow via cerebrovascular V1a receptor engagement, providing an additional mechanistic angle for the cognitive-endpoint research.
- 7Direct effects on hippocampal long-term potentiation and memory-consolidation-relevant neural activity, providing cellular-level substrates for the observed cognitive endpoints.
- 8Modulation of social-behaviour neurocircuitry via central V1a receptor engagement, providing overlap with the oxytocin social-cognition research framework.
Section 4
Researched Benefits
Findings reported in the published preclinical and clinical literature. Effects in research contexts do not constitute claims of therapeutic benefit in humans.
- 1Licensed clinical use with substantial post-marketing safety database and clinical-experience framework.
- 2Documented central memory-modulation effects in the classical vasopressin-family cognitive-research literature.
- 3Historical foundational significance as the parent compound of the vasopressin-family cognitive research programme.
- 4Well-characterised pharmacology across peripheral and central effects.
- 5Substantial acute and chronic safety database from decades of licensed clinical use.
- 6Endogenous nonapeptide status providing a partial safety floor at physiological concentrations.
- 7Available as licensed pharmaceutical rather than research chemical.
Section 5
Theoretical Dosing & Protocols
| Route | Dosage | Frequency | Duration | Source |
|---|---|---|---|---|
| Subcutaneous or intramuscular injection (argipressin, licensed clinical use) | Licensed dose for diabetes insipidus when not of nephrogenic origin (SmPC): 0.25 mL to 1 mL (5 to 20 units) of the 20 IU/ml solution | Every four hours | Not stated in section 4.2 of the SmPC | emc SmPC: Argipressin 20 IU/ml solution for injection (section 4.2) |
| Intravenous infusion (argipressin, licensed clinical use) | Licensed dose for the initial control of oesophageal variceal bleeding (SmPC): 20 units diluted in 100 mL of 5% w/v dextrose, which may be infused over a 15 minute period | Not stated in section 4.2 of the SmPC | Not stated in section 4.2 of the SmPC | emc SmPC: Argipressin 20 IU/ml solution for injection (section 4.2) |
Note: Not approved for cognitive indications. The peripheral pressor and antidiuretic effects complicate research-context cognitive-endpoint use.
Note: Licensed haemorrhage indication only; not a cognitive dose.
Section 6
Administration Routes
- Intravenous administration — a licensed clinical route for acute clinical use.
- Subcutaneous administration in some clinical protocols.
- Intranasal administration explored in the classical cognitive-effect research literature.
- Intramuscular administration in some clinical settings.
- Oral administration is not viable — the peptide is degraded by gastrointestinal proteases.
Section 7
Safety Profile
Commonly reported
- · Hypertensive reactions via the V1a-mediated pressor effect — the licensed clinical-use adverse-event signal that limits parent vasopressin research use.
- · Nausea and mild abdominal discomfort.
- · Headache — common at initial doses.
- · Hyponatraemia via the V2-mediated antidiuretic mechanism.
- · Occasional facial flushing.
Rare / theoretical
- · Severe cardiovascular events (myocardial infarction, arrhythmia) at high doses via the V1a pressor mechanism — the most clinically-significant rare adverse event.
- · Severe hyponatraemia with neurological complications (seizures, coma) at high doses or in susceptible patients.
- · Rare hypersensitivity reactions.
- · Rare thrombotic events reported at low frequency.
- · Water intoxication in the context of excessive fluid intake.
Contraindications
- · Uncontrolled hypertension.
- · Severe cardiovascular disease.
- · Hyponatraemia or history of significant hyponatraemia.
- · Pregnancy — the licensed clinical use is generally deferred until after delivery unless clinically necessary.
- · Severe renal impairment.
Section 8
UK & EU Regulatory Context
United Kingdom
Authorised in the UK as a prescription-only medicine: the electronic medicines compendium (emc) lists Argipressin 20 IU/ml Solution for Injection (indicated for diabetes insipidus when not of nephrogenic origin, and control of bleeding from oesophageal varices), checked 17 October 2026. Cognitive indications are not among those indications.
European Union
Not on the EMA's list of centrally authorised medicines (checked 17 October 2026). Cognitive-endpoint use is investigational.
Section 9
Clinical Studies Summary
De Wied laboratory vasopressin-family cognitive-effect research
The extended body of foundational work from the De Wied laboratory in Utrecht demonstrating pro-memory effects of vasopressin and its analogues in animal and human research, providing the mechanistic and phenomenological scaffold for the vasopressin-family cognitive-effect research programme. Established the foundational concept that peptide hormones could be engineered as memory-modulating research tools.
Vasopressin memory effects in age-related cognitive decline
Classical vasopressin-family cognitive research reporting memory-modulation effects in age-related-cognitive-decline populations following intranasal or parenteral vasopressin administration. Effect sizes were modest and replicability was inconsistent across research groups; the results contributed to the historical vasopressin-cognitive-effect research angle.
Vasopressin V1a receptor engagement in memory neurocircuitry
Molecular and behavioural characterisation of vasopressin's V1a receptor engagement on hippocampal and amygdalar neuronal populations relevant to memory consolidation and retrieval, providing the mechanism-of-action scaffold for the observed memory-modulation effects.
Vasopressin in social-behaviour neurocircuitry research
Research characterising vasopressin's central V1a receptor engagement in social-behaviour neurocircuitry, extending the pharmacological framework beyond memory-modulation into social-cognition and pair-bonding research contexts (particularly in prairie-vole research). Provides the mechanistic overlap with the oxytocin social-cognition research framework.
Section 10
Frequently Asked Questions
Section 10a